Cerulean Pharma is a private biopharmaceutical company focused on the development
of novel, nanotechnology-based therapeutics in the areas of oncology, cardiovascular,
autoimmune and inflammatory diseases.
Cerulean is pursuing three key strategies to achieve leadership in Nanopharmaceuticals:
- Cerulean is focused on achieving rapid and clinically significant human
proof of concept with its technology.
- Cerulean is building a deep and diversified product pipeline, leveraging
its proprietary nanotechnology platform.
- Cerulean is using a multi-faceted business model, with plans to retain
certain key products for development and commercialization to achieve full
company value creation, while at the same time collaborating on other products
to leverage the resources and capabilities of partners.
Cerulean has assembled a world-class management team, board of directors and
scientific advisory board that collectively have a significant track record
of business building, product development and scientific breakthroughs. Cerulean
was founded in 2006 and is located in Cambridge, Massachusetts.